In Segment A, members will acquire various doses and schedules of oral ABBV-744 tablet to detect safe dosing regimen. More contributors will likely be enrolled within the identified monotherapy dosign regimen. In Segment B, members will get oral ruxolitinib and ABBV-744 will likely be specified as "add-on" therapy. In Segment https://zbignieww009hrd2.blog4youth.com/profile